Project Grant HT9425261E079
Award Date 9/30/26
Completion Date 9/29/28
Dollars Obligated $350K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles a $799,999 Project Grant on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support the project "From H&E to HRD: Linking Morphometry, Clinical, and Molecular Data for Drug Response Prediction." The award, with an ultimate completion date of April 30, 2030, funds biomedical research aimed at integrating histopathological imaging...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $700,000 Project Grant to the University of California, Los Angeles (UCLA) beginning June 1, 2026, through May 31, 2030, under the Military Medical Research and Development program (CFDA 12.420). The project, titled "Early Detection of Ovarian Cancer with cfDNA Methylome Sequencing and Protein Biomarkers," focuses on developing innovative diagnostic approaches for ovarian cancer screening. The research will utilize...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles a $2.08 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) beginning September 1, 2026, and concluding August 31, 2030. The award supports research to define an error-free DNA repair signature as a predictive marker for lethal prostate cancer. This research initiative aligns with the DHA's broader portfolio of biomedical research addressing...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $235,476 project grant to the University of California, Los Angeles (UCLA) Office of Research Administration on November 1, 2025, to develop new cell-mediated immunotherapeutic strategies for neuroendocrine prostate cancer. The two-year award, which concludes October 31, 2027, is funded under the Military Medical Research and Development program (CFDA 12.420) and will be conducted at UCLA's Los Angeles, California facility....
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded a $1.75 million Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, with a completion date of August 31, 2029. This three-year award funds biomedical research to deconstruct adeno-associated virus (AAV)-associated liver toxicity through the identification and characterization of biomarkers and immune...
- Federal Project Grant Award Summary The Defense Health Agency (DHA), through its Military Medical Research and Development program (CFDA 12.420), awarded a $157,500 Project Grant to the University of California, Los Angeles (UCLA) Office of Research Administration, effective September 1, 2025, with completion scheduled for August 31, 2026. The award supports research investigating the impact of a hypomorphic SMARCB1 germline allele specific for schwannomatosis on mouse development and...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles a $2.1 million Project Grant on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop mechanistically guided drug combinations from large language model (LLM)-based digital twins of prostate tumors. The four-year project, scheduled for completion on July 31, 2030, will leverage artificial intelligence and computational modeling to identify...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded a $7.99 million Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420) to conduct a Phase 1 single-blind, placebo-controlled, dose escalation clinical safety study of AD-NP1, a humanized monoclonal antibody targeting human enpp1 (ectonucleotide pyrophosphatase/phosphodiesterase 1). The award, effective August 1, 2026, through July 31,...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $1.7M Project Grant effective July 1, 2026, through June 30, 2029, under the Military Medical Research and Development program (CFDA 12.420) to conduct functional evaluation and optimization of chimeric antigen receptor T (CAR-T) cells targeting prostate cancer. The research will employ cell-cell interaction profiling using engineered nanovials as the primary analytical technology platform. This work addresses the DHA's...
- Federal Grant Award Summary The University of California, Los Angeles received a $1.7M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "The 3D Multiomic Determinants of Prostate Cancer Lethality." Awarded on June 1, 2026, with a completion date of May 31, 2029, this three-year initiative will investigate the molecular and genetic factors that drive prostate cancer progression and...